

OncoTherapy Science, Inc.

May 16, 2016

Patent Registration for TOPK-specific inhibitors in China

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that a substance patent issued by OncoTherapy for the TOPK (T-LAK cell-originated protein kinase) -specific inhibitors was approved in China.

Patent No. ZL201180026805.8

Country: China

Title of invention: Tricyclic compounds and PBK inhibitors containing the same (PBK=TOPK)

As announced by us, the equivalent patent for the TOPK-specific inhibitors has already been approved in the United States of America and in Japan.

TOPK is one of the novel anti-cancer drug targets identified by the genome-wide gene expression analyses conducted by Professor Yusuke Nakamura’s laboratory. It is highly expressed in various types of human cancer including breast and lung cancers, while its expression was hardly detectable in any normal tissues except testis. It is therefore expected that a drug acting on TOPK can be applied to a wide range of human cancers with a minimum risk of adverse side effects.

As we announced on October 6, 2015 in the release titled “Publication from The University of Chicago and OncoTherapy Science”, TOPK inhibitors are expected to be very effective to FLT3-ITD-mutated acute myeloid leukemia (AML), which is known to show very poor prognosis among AMLs.

We will accelerate the development of drugs targeting TOPK to contribute to the improvement of cancer treatment.